SCULPTRA AND SCULPTRA AESTHETIC
Q-Med AB · Decision date Apr 15, 2026
What did the FDA approve?
FDA records P030050/S054 as a supplement to PMA P030050, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 15, 2026.
FDA approval order statement
Approval to terminate elemental impurity testing for Sculptra vial stoppers
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Apr 15, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P030050/S054
- Regulatory pathway
- PMA supplement
- Applicant
- Q-Med AB
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Apr 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
For the original device and its historical approval scope, see PMA P030050. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030050 · Original PMA
SCULPTRA AND SCULPTRA AESTHETIC
P030050/S054 received
Application receipt date recorded by FDA.
P030050/S054 · FDA decision
Real-Time Process
P030050/S055 · Related supplement
SCULPTRA (injectable poly-L Lactic acid)
P030050/S056 · Related supplement
SCULPTRA (injectable poly-L Lactic acid)
Timeline entries are records held by MedtechLedger for P030050. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030050
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Q-Med AB | PMA approval | Aug 3, 2004 | FDA | |
SCULPTRA (injectable poly-L Lactic acid)P030050/S055 | Q-Med AB | PMA supplement | Jun 22, 2026 | FDA |
SCULPTRA (injectable poly-L Lactic acid)P030050/S056 | Q-Med AB | PMA supplement | Sep 17, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Q-Med AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seminariegatan 21, Uppsala, SE-752-28
Sources and methodology
- Original FDA record: P030050/S054
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




